Platform Discovery & Validation
Oncology
DiscoveryActive
Key Facts
About Kahimmune Therapeutics
Kahimmune Therapeutics is an early-stage biotech developing cancer immunotherapies based on targets from the dark genome, a largely unexplored area of non-coding DNA. Its platform aims to discover and validate novel tumor antigens to create potent and specific vaccines and immunotherapies with the potential for improved safety and efficacy. As a private, pre-revenue company, it is likely in a foundational or pre-clinical research phase, building its scientific platform and initial pipeline. The company's success hinges on validating its novel approach, securing sustained funding, and navigating the highly competitive oncology immunotherapy landscape.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |